Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia

Basit Öğe Kaydı
dc.authorid0000-0002-4075-6692en_US
dc.contributor.authorAkyol Erikçi, Alev
dc.contributor.authorÖztürk, Ahmet
dc.contributor.authorKaragöz, Bülent
dc.contributor.authorBilgi, Oğuz
dc.contributor.authorTop, Cihan
dc.contributor.authorKandemir, E. Gökhan
dc.date.accessioned2024-07-12T21:04:02Z
dc.date.available2024-07-12T21:04:02Z
dc.date.issued2008en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractMyelodysplastic syndrome (MDS) is a clonal disease of the bone marrow characterized by abnormal hematopoiesis and cytopenias. It has been shown that abnormal cytokine production together with apoptosis are major contributors to the cytopenias associated with the disorder. As the interaction of cytokines plays a role in the pathogenesis, suppression of the cytokine production by the administration of the combination of pentoxyfilline, ciprofloxacin, and dexamethasone (PCD combination) has resulted in the correction of at least some aspects of the cytopenias in the majority of patients and in complete hematologic remission in a small percentage. The aminothiol prodrug amifostine, a compound to protect tissues from cytotoxic drugs and radiotherapy has been found to stimulate proliferation of normal hematopoesis and suppress apoptosis in patients with MDS. In this study we report the results of combination therapy of amifostine and PCD in 12 patients with MDS and acute myeloid leukemia (AML). Amifostine was given in a dose of 200 mg/m2, as an i.v. infusion administered in 10 min, three times a week; pentoxyfilline 2400 mg/day, (3 × 800 mg) p.o.; ciprofloxacine, 1 g/day p.o.; dexamethasone 4·5 mg/day p.o. We achieved 66% response rate in our patients. In some cases responses were achieved in only thrombocytopenia or anemia whereas in others responses were achieved in multiple series. As a result it was found that amifostine + PCD combination may be beneficial in reversing cytopenias in the treatment of MDS and AML and is worth further study.en_US
dc.identifier.citationErikci, A. A., Ozturk, A., Karagoz, B., Bilgi, O., Turken, O., Top, C. ve Kandemir, E. G. (2008). Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia. Hematology, Taylor and Francis Online. 13(5), s. 289–292.en_US
dc.identifier.endpage292en_US
dc.identifier.issn1607-8454
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage289en_US
dc.identifier.urihttps://www.tandfonline.com/doi/abs/10.1179/102453308X343428
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3746
dc.identifier.volume13en_US
dc.institutionauthorTürken, Orhan
dc.language.isoenen_US
dc.publisherTaylor and Francis Onlineen_US
dc.relation.ispartofHematologyen_US
dc.relation.isversionof10.1179/102453308X343428en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY01185
dc.subjectMyelodysplastic syndromeen_US
dc.subjectacute myeloid leukemiaen_US
dc.subjectamifostineen_US
dc.subjectpentoxifyllineen_US
dc.subjectciprofloxacin and dexamethasoneen_US
dc.titleResults of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemiaen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu